Biologic therapy significantly improves pregnancy outcomes in women with antiphospholipid syndrome

A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes in women with antiphospholipid syndrome (APS).

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup